ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.04
0.60%
US Tech 100
17,446.00
2.17%
S&P 500
5,127.79
1.26%
US Dollar vs CAD
1.36685
0.00%
Bitcoin
63,864.70
-0.04%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Ultragenyx Pharmaceutical Inc (RARE)

  7. Ultragenyx Pharmaceutical Inc (RARE) News

RARE Ultragenyx Pharmaceutical Inc

42.75
-0.45 (-1.04%)
May 03 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Ultragenyx Pharmaceutical Inc RARE NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
-0.45 -1.04% 42.75 19:00:00
Open Price Low Price High Price Close Price Previous Close
44.88 42.675 46.005 42.75 43.20
more quote information »

Recent News

Date Time Source Heading
5/02/202415:00GLOBEUltragenyx Reports First Quarter 2024 Financial Results and..
4/30/202415:00GLOBEUltragenyx Issues 2023 Corporate Responsibility Report,..
4/30/202407:00GLOBEUltragenyx Announces Completion of Enrollment in Phase 3..
4/25/202415:30GLOBEUltragenyx to Host Conference Call for First Quarter 2024..
4/19/202415:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
4/15/202406:00GLOBEUltragenyx Announces Positive Interim Phase 1/2 Data in..
4/12/202415:22GLOBEUltragenyx Announces Update to Conference Call Timing to..
4/12/202407:00GLOBEUltragenyx Announces Upcoming Data Presentations at American..
3/22/202415:00GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
3/05/202419:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/05/202419:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/05/202419:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/05/202419:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/05/202419:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/05/202419:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/05/202419:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/27/202415:30GLOBEUltragenyx to Participate at Investor Conferences in March
2/23/202415:05GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
2/21/202416:03EDGAR2Form S-3ASR - Automatic shelf registration statement of..
2/15/202415:04EDGAR2Form 8-K - Current report
2/15/202415:01GLOBEUltragenyx Reports Fourth Quarter and Full Year 2023..
2/08/202415:00GLOBEUltragenyx to Host Conference Call for Fourth Quarter and..
2/06/202407:00GLOBEUltragenyx Announces Data Demonstrating Treatment with UX111..
2/05/202415:05GLOBEUltragenyx Receives PRIME Designation from European..
1/25/202415:05GLOBEUltragenyx Announces Completion of Dosing Across Stage 1..
1/19/202415:00GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
1/08/202406:00GLOBEMereo BioPharma Provides Update on Pipeline Progress and..
1/08/202405:03EDGAR2Form 8-K - Current report
1/07/202410:00GLOBEUltragenyx Reports Preliminary 2023 Revenue; Guidance for..
1/04/202407:00GLOBEUltragenyx Receives Positive Recommendation from NICE in the..
1/03/202407:00GLOBEUltragenyx Announces Completion of Enrollment in Global..
1/02/202415:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/02/202415:05GLOBEUltragenyx to Present at the 42nd Annual J.P. Morgan..
12/21/202316:45DJNUltragenyx to Pay $6 Million to Settle Alleged False..
12/21/202315:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
12/21/202315:02EDGAR2Form 8-K - Current report
12/18/202307:00GLOBEUltragenyx Receives European Commission Decision for..
11/20/202315:30GLOBEUltragenyx to Participate at Investor Conferences in..
11/17/202315:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
11/07/202316:00GLOBEUltragenyx to Participate in the Jefferies London Healthcare..
11/02/202315:17EDGAR2Form 8-K - Current report
11/02/202315:05GLOBEUltragenyx Reports Third Quarter 2023 Financial Results and..
10/26/202315:05GLOBEUltragenyx to Host Conference Call for Third Quarter 2023..
10/23/202315:01GLOBEUltragenyx Announces Closing of Public Offering of Common..
10/23/202305:31EDGAR2Form 8-K - Current report
10/20/202315:00GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
10/20/202305:31EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/18/202320:16GLOBEUltragenyx Announces Pricing of Public Offering of Common..
10/17/202315:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/17/202315:02GLOBEUltragenyx Announces Proposed Public Offering of Common..

Your Recent History

NASDAQ
RARE
Ultragenyx Pharmaceutical
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved